^
    Back
    Association details:
    Biomarker:CCR7 expresion
    Cancer:Chronic Lymphocytic Leukemia
    Drug:CAP-100 (CCR7 receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2019
    Title:

    CAP-100: First-in-class antibody for CCR7+ hematological malignancies.

    Published date:
    05/26/2019
    Excerpt:
    ...CAP-100 was shown to inhibit entry of CCR7-expressing cells to LNs...CAP-100 also abrogated survival elicited by CCR7 in CLL, and showed potent cell killing activity against CLL or CCR7+ T-lymphomas cells. 
    DOI:
    10.1200/JCO.2019.37.15_suppl.e19008